Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics appeals FDA decision

Cell Therapeutics has submitted a formal appeal to the US FDA challenging the federal agency's negative decision on the company's investigational treatment for non-Hodgkin's lymphoma
Cell Therapeutics has submitted a formal appeal to the US Food and Drug Administration (FDA) challenging the federal agency's negative decision on the company's investigational treatment for non-Hodgkin's lymphoma (NHL). 

The appeal, filed with the Office of New Drugs in the FDA's Center for Drug Evaluation and Research, argues that the FDA improperly analysed a late-stage clinical trial of the drug pixantrone for relapsed/refractory aggressive NHL. In a Complete Response Letter issued to the company in April, the FDA's Office of Oncology Drugs said that it would require an additional clinical trial before the drug could be approved because the study submitted in the New Drug Application (NDA), known as PIX301, did not demonstrate efficacy.

The NDA for pixantrone is seeking marketing clearance through the FDA's accelerated approval programme, under which drugs that meet urgent unmet medical needs can be approved based on surrogate endpoints.

Cell Therapeutics noted that it already had plans in place for another clinical trial before it received the Complete Response Letter. The additional trial, known as PIX306, was planned by the company to serve as either a post-approval confirmatory trial or a second registration trial for approval. However, the company nonetheless objects to the conclusion that the PIX301 trial failed to demonstrate efficacy and argues that the decision was made based on faulty practices.

The company asserts that the FDA applied a stringent statistical significance level that is intended to be used if an interim analysis has been conducted, which was not the case with the pixantrone trial, in which only a final analysis was undertaken. "We believe the results of the PIX301 clinical trial should be analysed with the appropriate threshold that is standard for trials of this type in which only one efficacy analysis was conducted," said Richard Kay of the School of Pharmacy, Cardiff University, who is serving as a consultant for the company on the matter. 

Cell Therapeutics said it expects a decision on the appeal in the first quarter of 2011. Meanwhile, the company is preparing for the second trial and has filed a Marketing Authorisation Application with the European Medicines Agency (EMA), which was accepted for review on November 17.

3rd December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics